David Stover has been appointed CEO of Boulder, CO-based cancer drug developer i2 Pharmaceuticals. Stover was most recently an executive at Agensys, a Santa Monica, CA, oncology subsidiary of Japanese company Astellas Pharma. Last year, Astellas announced it would shutter Agensys as part of its strategy to refine its research focus in cancer. Stover’s cancer research experience also includes stints at Novartis (NYSE: NVS) and MDS Proteomics. The i2 drug pipeline includes drug candidates based on the antibody and protein technology it acquired last year from Redwood City, CA-based Sea Lane Biotechnologies.